Inhibitor(s) | % of Met-enk-RGL and Its Hydrolysis Products | |||||||
---|---|---|---|---|---|---|---|---|
Y | YG | YGG | YGGF | YGGFM | YGGFMR | YGGFMRG | met-enk-RGL | |
None | 76.3 ± 0.3 | 7.2 ± 0.2 | 1.3 ± 0.2 | 13.3 ± 0.4 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 |
Ama | 1.5 ± 0.2 | 54.3 ± 0.6 | 7.2 ± 0.2 | 28.2 ± 0.5 | 0.0 ± 0.0 | 4.0 ± 0.3 | 0.0 ± 0.0 | 3.0 ± 1.2 |
Cap | 59.1 ± 0.3 | 4.4 ± 0.3 | 0.5 ± 0.1 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 33.4 ± 0.4 |
Pho | 77.3 ± 0.6 | 8.0 ± 0.2 | 0.0 ± 0.0 | 13.1 ± 0.4 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 |
Ama + Cap | 3.0 ± 0.3 | 0.4 ± 0.0 | 38.6 ± 0.6 | 0.6 ± 0.1 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 56.3 ± 0.2 |
Ama + Cap + Pho | 2.2 ± 0.4 | 0.5 ± 0.1 | 0.0 ± 0.0 | 0.3 ± 0.2 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 95.0 ± 0.4 |
The membrane fraction (0.5 mg of protein) in 50 mM Tris-HCl buffer (pH 7.4) was incubated with met-enk-RGL (5 nmol) in either the absence or the presence of the PIs at the final concentration of 1 μM each for 60 min at 37°C. Ama, amastatin; Cap, captopril; Pho, phosphoramidon.